221 related articles for article (PubMed ID: 30110637)
1. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
[TBL] [Abstract][Full Text] [Related]
2. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
[TBL] [Abstract][Full Text] [Related]
3. Presence and Persistence of Ebola or Marburg Virus in Patients and Survivors: A Rapid Systematic Review.
Brainard J; Pond K; Hooper L; Edmunds K; Hunter P
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004475. PubMed ID: 26927697
[TBL] [Abstract][Full Text] [Related]
4. Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model.
Duehr J; Wohlbold TJ; Oestereich L; Chromikova V; Amanat F; Rajendran M; Gomez-Medina S; Mena I; tenOever BR; García-Sastre A; Basler CF; Munoz-Fontela C; Krammer F
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592526
[TBL] [Abstract][Full Text] [Related]
5. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.
Gunn BM; Lu R; Slein MD; Ilinykh PA; Huang K; Atyeo C; Schendel SL; Kim J; Cain C; Roy V; Suscovich TJ; Takada A; Halfmann PJ; Kawaoka Y; Pauthner MG; Momoh M; Goba A; Kanneh L; Andersen KG; Schieffelin JS; Grant D; Garry RF; Saphire EO; Bukreyev A; Alter G
Immunity; 2021 Apr; 54(4):815-828.e5. PubMed ID: 33852832
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
Wirchnianski AS; Nyakatura EK; Herbert AS; Kuehne AI; Abbasi SA; Florez C; Storm N; McKay LGA; Dailey L; Kuang E; Abelson DM; Wec AZ; Chakraborti S; Holtsberg FW; Shulenin S; Bornholdt ZA; Aman MJ; Honko AN; Griffiths A; Dye JM; Chandran K; Lai JR
PLoS Pathog; 2024 Apr; 20(4):e1012134. PubMed ID: 38603762
[TBL] [Abstract][Full Text] [Related]
7. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.
Iversen PL; Warren TK; Wells JB; Garza NL; Mourich DV; Welch LS; Panchal RG; Bavari S
Viruses; 2012 Nov; 4(11):2806-30. PubMed ID: 23202506
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.
Ilinykh PA; Santos RI; Gunn BM; Kuzmina NA; Shen X; Huang K; Gilchuk P; Flyak AI; Younan P; Alter G; Crowe JE; Bukreyev A
PLoS Pathog; 2018 Aug; 14(8):e1007204. PubMed ID: 30138408
[TBL] [Abstract][Full Text] [Related]
9. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Murin CD; Gilchuk P; Crowe JE; Ward AB
Front Immunol; 2021; 12():808047. PubMed ID: 35082794
[TBL] [Abstract][Full Text] [Related]
10. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.
Wec AZ; Nyakatura EK; Herbert AS; Howell KA; Holtsberg FW; Bakken RR; Mittler E; Christin JR; Shulenin S; Jangra RK; Bharrhan S; Kuehne AI; Bornholdt ZA; Flyak AI; Saphire EO; Crowe JE; Aman MJ; Dye JM; Lai JR; Chandran K
Science; 2016 Oct; 354(6310):350-354. PubMed ID: 27608667
[TBL] [Abstract][Full Text] [Related]
11. A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses.
Liu G; He S; Chan M; Zhang Z; Schulz H; Cao W; Rahim MN; Audet J; Garnett L; Wec A; Chandran K; Qiu X; Banadyga L
J Infect Dis; 2023 Nov; 228(Suppl 7):S691-S700. PubMed ID: 37288609
[TBL] [Abstract][Full Text] [Related]
12. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.
Zhao X; Howell KA; He S; Brannan JM; Wec AZ; Davidson E; Turner HL; Chiang CI; Lei L; Fels JM; Vu H; Shulenin S; Turonis AN; Kuehne AI; Liu G; Ta M; Wang Y; Sundling C; Xiao Y; Spence JS; Doranz BJ; Holtsberg FW; Ward AB; Chandran K; Dye JM; Qiu X; Li Y; Aman MJ
Cell; 2017 May; 169(5):891-904.e15. PubMed ID: 28525756
[TBL] [Abstract][Full Text] [Related]
13. The mechanistic basis of protection by non-neutralizing anti-alphavirus antibodies.
Earnest JT; Holmes AC; Basore K; Mack M; Fremont DH; Diamond MS
Cell Rep; 2021 Apr; 35(1):108962. PubMed ID: 33826892
[TBL] [Abstract][Full Text] [Related]
14. Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.
Rahim MN; Wee EG; He S; Audet J; Tierney K; Moyo N; Hannoun Z; Crook A; Baines A; Korber B; Qiu X; Hanke T
PLoS Pathog; 2019 Feb; 15(2):e1007564. PubMed ID: 30817809
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.
Mire CE; Geisbert JB; Borisevich V; Fenton KA; Agans KN; Flyak AI; Deer DJ; Steinkellner H; Bohorov O; Bohorova N; Goodman C; Hiatt A; Kim DH; Pauly MH; Velasco J; Whaley KJ; Crowe JE; Zeitlin L; Geisbert TW
Sci Transl Med; 2017 Apr; 9(384):. PubMed ID: 28381540
[TBL] [Abstract][Full Text] [Related]
16. Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization.
Janus BM; Wang R; Cleveland TE; Metcalf MC; Lemmer AC; van Dyk N; Jeong S; Astavans A; Class K; Fuerst TR; Ofek G
J Virol; 2024 Jun; ():e0015524. PubMed ID: 38832790
[TBL] [Abstract][Full Text] [Related]
17. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors.
Sahin M; Remy MM; Fallet B; Sommerstein R; Florova M; Langner A; Klausz K; Straub T; Kreutzfeldt M; Wagner I; Schmidt CT; Malinge P; Magistrelli G; Izui S; Pircher H; Verbeek JS; Merkler D; Peipp M; Pinschewer DD
Cell Rep; 2022 Feb; 38(5):110303. PubMed ID: 35108544
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity.
Earnest JT; Basore K; Roy V; Bailey AL; Wang D; Alter G; Fremont DH; Diamond MS
J Exp Med; 2019 Oct; 216(10):2282-2301. PubMed ID: 31337735
[TBL] [Abstract][Full Text] [Related]
19. Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin.
Santos RI; Ilinykh PA; Pietzsch CA; Ronk AJ; Huang K; Kuzmina NA; Zhou F; Crowe JE; Bukreyev A
Cell Rep; 2023 Oct; 42(10):113254. PubMed ID: 37858466
[TBL] [Abstract][Full Text] [Related]
20. AAV-Vectored Expression of Marburg Virus-Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model.
Rghei AD; Cao W; He S; Lopes JA; Zielinska N; Pei Y; Thompson B; Banadyga L; Wootton SK
J Infect Dis; 2023 Nov; 228(Suppl 7):S682-S690. PubMed ID: 37638865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
